AAA acquires GE's FDG-PET sector in Italy

Advanced Accelerator Applications (AAA) announced today that it has acquired GE Healthcare’s FDG-PET radiopharmaceutical division in Italy.

Based in Saint-Genis-Pouilly, France, AAA specializes in radiopharmaceuticals for molecular imaging and therapy. The company is now licensed under the agreement to market GE’s FDG radiopharmaceutical known as SteriPET. AAA’s own FDG product is marketed as Gluscan. Both are used in a range of nuclear medicine procedures, but most notably oncologic applications.

“This acquisition is in line with AAA’s growth strategy of further consolidating our position as a leading pan-European nuclear diagnostics company, alongside exploring additional product pipeline opportunities and avenues for expansion in the United States and outside Europe,” said Stefano Buono, chief executive officer of AAA, in the press release.

The director of AAA in Italy, Enrico De Maria, added that the cost of these products should be in line with recent trends keeping FDG at a modest price. The PET production centers under AAA’s umbrella are spread across France, Spain, Poland, Germany, Portugal and Italy—13 in all. 

AAA was established in 2002 and continues to produce six diagnostic and therapeutic products for SPECT and PET including the investigational Lu-DOTATATE. A phase III clinical trial for the latter is underway in 51 research centers through Europe and the U.S.